13.80
-0.03(-0.22%)
Currency In USD
| Previous Close | 13.83 |
| Open | 13.83 |
| Day High | 14.28 |
| Day Low | 13.41 |
| 52-Week High | 20.9 |
| 52-Week Low | 7 |
| Volume | 138,251 |
| Average Volume | 110,943 |
| Market Cap | 285.42M |
| PE | -3.29 |
| EPS | -4.2 |
| Moving Average 50 Days | 16.6 |
| Moving Average 200 Days | 14.02 |
| Change | -0.03 |
If you invested $1000 in Amarin Corporation plc (AMRN) 10 years ago, it would be worth $361.26 as of December 21, 2025 at a share price of $13.8. Whereas If you bought $1000 worth of Amarin Corporation plc (AMRN) shares 5 years ago, it would be worth $137.45 as of December 21, 2025 at a share price of $13.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
GlobeNewswire Inc.
Nov 09, 2025 9:15 PM GMT
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinf
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
GlobeNewswire Inc.
Nov 03, 2025 1:30 PM GMT
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Ass
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement in response to the recent acti